GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.
